Treo Ventures

Neuspera Medical Inc. specializes in the development and manufacture of ultra-miniaturized implantable devices designed for neuromodulation therapy, often referred to as "electroceuticals." Utilizing licensed mid-field powering technology, these devices leverage the body as a natural waveguide to deliver energy effectively. Founded in 2013 and based in San Jose, California, Neuspera aims to enhance the quality of life for patients dealing with chronic illnesses by providing less invasive and adaptable treatment options. The company's innovative approach allows for deeper implantation of its devices, offering patients new possibilities in managing their health conditions.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device accelerator company.

NeoChord, Inc. is a medical technology company that specializes in developing devices to address degenerative mitral valve disease (DMR), a condition that can lead to serious complications such as atrial fibrillation and congestive heart failure. The company's flagship product is the NeoChord Artificial Chordae Delivery System, a disposable device designed to repair damaged heart chordae through a small incision while the heart continues to beat. This innovative approach allows for mitral valve repair to be performed via a 2 to 3-inch incision between the ribs, significantly less invasive than traditional methods that require larger incisions and the use of heart-lung machines. Founded in 2007, NeoChord is headquartered in St. Louis Park, Minnesota.

Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.